Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Lexaria Bioscience Corp. (LEXX) is a Biotechnology company based in CA with a market capitalization of $13.9M. Revenue grew 52.0% year-over-year and free cash flow was negative at -$10.5M. This page tracks LEXX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
CA · 7 employees · IPO Jan 12, 2021
Valuation
Valuation & price
$0.59as of May 17, 2026· -61.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
4.63
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$13.9M
Market cap
52.0%
Revenue growth (YoY)
99.6%
Gross margin
-$10.5M
Free cash flow (USD)
-$1.9M
Net debt
Net cash position
45.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: Jul 13, 2026 (EPS $-0.08)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Lexaria Bioscience Corp.'s market cap?
Lexaria Bioscience Corp. (LEXX) has a market capitalization of $13.9M.
What is LEXX's P/E ratio?
A meaningful P/E ratio is not available for LEXX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LEXX's price-to-book (P/B) ratio?
LEXX trades at 4.63 times book value per share.
When did Lexaria Bioscience Corp. last report earnings?
LEXX last reported earnings on July 13, 2026; the next date is not yet scheduled.
Are insiders buying LEXX stock?
SEC Form 4 filings show no open-market insider buys at Lexaria Bioscience Corp. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.